Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. - Wikidata - wikimedia - TriplyDB

Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production.

Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production.

http://www.wikidata.org/entity/Q33737672

about

The great escape: viral strategies to counter BST-2/tetherin Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2 HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms BST-2/tetherin: a new component of the innate immune response to enveloped viruses Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction The role of BST-2/Tetherin in host protection and disease manifestation Conformational changes induced by a single amino acid substitution in thetrans-membrane domain of Vpu: Implications for HIV-1 susceptibility to channel blocking drugs Tetherin/BST-2: Restriction Factor or Immunomodulator?Lack of adaptation to human tetherin in HIV-1 group O and P.HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane.Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.HIV protein sequence hotspots for crosstalk with host hub proteins.Molecular regulation of lysophosphatidic acid receptor 1 trafficking to the cell surface.The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor?Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV Nef proteins from simian immunodeficiency viruses are tetherin antagonists.The role of BST2/tetherin in feline retrovirus infection Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis.Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens Antibody-mediated enhancement of HIV-1 and HIV-2 production from BST-2/tetherin-positive cells.Structural Basis for the Antiviral Activity of BST-2/Tetherin and Its Viral Antagonism HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation.Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and Spectra.Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu.Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism.Human cellular restriction factors that target HIV-1 replication.Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates.Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration.Potential of carbohydrate-binding agents as therapeutics against enveloped viruses.Tetherin and its viral antagonists.Inhibition of budding/release of porcine endogenous retrovirus.Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts.Anti-tetherin activities in Vpu-expressing primate lentiviruses.Endogenous CD317/Tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses.HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein.An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein.

P2860

Q21090506-DCB717F0-7F28-4104-BA62-C42246C4059F Q21559418-A228BE12-0DA5-4052-AE54-6DC8BFE8E994 Q24619066-0ABC3F6E-5D27-4467-9489-A1E5B4D756F4 Q24630382-0C485FF2-B58F-49B9-A0CA-45D68E9287B7 Q24635271-9A49A493-746B-4CDE-84CF-2F8F07489C5C Q26752737-D4A5A0BF-7C42-4BC3-A450-8DE6EB99EEE7 Q27647751-97E3097A-0F51-4FCA-A20D-6AF13C7ABB9D Q30385433-86A4A734-5C3A-4C83-804E-3847E4140999 Q30407564-A1E198AF-E7BF-4580-B164-20B6D3BFD107 Q30815492-A0395A33-E1FD-4DB0-8519-A006670FF919 Q33408799-653768D6-7C56-4E17-ADFD-23ED504B8703 Q33450556-67B5EF8F-C01C-4FC1-9F46-8D0F40036B88 Q33807551-66FF22D8-78C2-46A3-9055-556D8DA35C34 Q33999393-BEEDFC76-6E12-4A1F-BC10-1B0D62030D32 Q34476196-E4560827-3830-4E7F-B694-0D66DB503A21 Q34492477-4047FE13-D62D-4F24-A9F3-18D112410BAA Q34505213-18BDD64A-5150-4EE2-8475-ACD76D307BBD Q34658653-8BC13942-B50D-4247-A6BA-C1986BD4BCF8 Q34664616-B71111BA-B391-4E74-8852-E7A567005A48 Q34819697-15E524F0-3FAB-4376-8236-9067FF8C1B43 Q35383008-5CA9B141-0929-4319-A36B-AA8BA33B689A Q35531194-5FB7268A-A275-4EBE-82F4-4CD3B09DE35D Q35607295-DB6E6C4F-5EE6-4EE1-9186-703A5CB2F3EA Q35834559-980CE816-9F61-426B-9552-4DE3836B5DE1 Q36371387-A692339C-739C-43AB-9F21-42AD44BEF3C9 Q37115285-4F1A001B-A4D1-4A03-9019-1182D0979468 Q37120188-EA54F50F-0B80-4068-8344-8593115AC832 Q37378819-B6538FF5-8A1B-47E1-812F-4BA6112397D4 Q37382519-FADC6AE8-1B87-4EDA-BE08-76FDA8D103B6 Q37448301-7A8E26E0-F08E-4383-992C-FD9BDF207E0A Q37469794-B64A437A-8737-4E5F-820E-CAE705021F31 Q37767654-DF7BE343-1D60-41DE-B355-ABF6280F1AF1 Q37827428-7940EF99-F99F-4D6C-93D6-A358BE3AA412 Q38984528-F7FAC605-9A70-41BB-A733-CE4C1F0A97F3 Q39383826-CC5C29A3-C982-4D82-B58E-9A93FE3CCB8E Q39391944-01715FB2-F614-468C-BAEC-ECA88DD6A5F2 Q39668496-2E0D7F3E-D544-4009-B7CF-48F75E5DF430 Q39696123-01A8E6F6-5AEF-49AC-9ADA-56FB76FE1A21 Q39801517-431F7ABC-797B-407B-AA7E-60D03454AD2F Q40051211-44EA7783-0819-4CBB-B788-DB81C7131CC8

P2860

Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production.

http://www.wikidata.org/entity/Q33737672

description

2005 nî lūn-bûn

@nan

2005 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մարտին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Functional domains within the ...... d to enhance virus production.

@ast

Functional domains within the ...... d to enhance virus production.

@en

type

label

Functional domains within the ...... d to enhance virus production.

@ast

Functional domains within the ...... d to enhance virus production.

@en

prefLabel

Functional domains within the ...... d to enhance virus production.

@ast

Functional domains within the ...... d to enhance virus production.

@en

P1433

Q33737672-0C8CA806-0A0C-4312-A920-C20C69993FFE

P1476

Q33737672-EDCDB269-45D0-4D6F-A538-4DB88F1D1E48

P2093

Q33737672-26F0C7DE-E382-43EC-A9E1-3F80ACDCDEAA

Q33737672-57EE4D95-EC7B-4F7F-8155-0442BBB12AF3

Q33737672-8B311E5D-F36A-4946-8ABD-7102BDC64ADF

P2860

Q33737672-02DEDE8F-B2B6-4385-9CDD-FBC919A5E63B

Q33737672-03292B4D-4A2D-4345-AE14-317E6C5E7EF0

Q33737672-06B1AF07-E1A7-4B85-8739-54F3BF88D8CC

Q33737672-0BB88494-842E-45F5-9F6E-C551017178C2

Q33737672-0FB01EE6-D586-4062-B677-FB4B6F9DC790

Q33737672-14D13D8D-766E-4C7A-9347-3A281BB5B937

Q33737672-16DC2318-A925-48BC-AE90-EDB67C17185A

Q33737672-183AB455-9087-4449-B245-B21461C752FD

Q33737672-198332D5-242A-4E58-8C07-B6C61B620549

Q33737672-19B640A8-979E-44BD-9B22-D63848557D41

P304

Q33737672-8CCA73A4-A3CD-41AE-92AD-0FC8F87A682A

P31

Q33737672-21F635EC-B252-4E5C-A58F-8D2D20EC9EB4

P356

Q33737672-66914573-06BD-4B63-B912-1973FAD65436

P433

Q33737672-97EEB032-3194-4C68-AC2A-CB2253A87997

P478

Q33737672-4C16FD8A-E42C-4F19-948E-4C4BA7A46AFE

P577

Q33737672-4D6D67AF-0972-4EFA-A13E-246522A4CD50

P698

Q33737672-0883F560-FE8E-4E1C-8C23-D557BB97C1CC

P932

Q33737672-684F3016-12F1-4B93-8CFF-722BD572C74C

P356

JVI.79.6.3627-3638.2005

P1433

Journal of Virology

P1476

Functional domains within the ...... d to enhance virus production.

@en

P2093

Beth Noble

http://www.w3.org/2001/XMLSchema#string

Paolo Abada

http://www.w3.org/2001/XMLSchema#string

Paula M Cannon

http://www.w3.org/2001/XMLSchema#string

P2860

The protein network of HIV budding

Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins

Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins

Functional interaction of human immunodeficiency virus type 1 Vpu and Gag with a novel member of the tetratricopeptide repeat protein family.

Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41

Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses

The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels

AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding

Cell type-dependence for Vpu function

Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel

P304

3627-3638

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.79.6.3627-3638.2005

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15731257

http://www.w3.org/2001/XMLSchema#string

P932

1075700

http://www.w3.org/2001/XMLSchema#string